National-, institutional-, and individual-level determinants of dermatologic research excellence: an analysis of Stanford-Elsevier Lists of the top 2% scholars worldwide (2017-2023)
Abstract
Background: Skin diseases contribute to a massive and often overlooked component of the global disease burden, highlighting the need for a better understanding of the dermatologic research landscape and its key drivers of excellence.
Aim: To explore the national, institutional, and individual-level determinants that shape dermatologic research excellence worldwide.
Methods: We analyzed the publicly available Stanford-Elsevier Lists of the top 2% most-cited scientists (2017-2023), extracting scholars classified in Dermatology & Venereal Diseases to identify excellent dermatologic scholars (EDS). EDS records were then linked, based on affiliation data, to country-level indicators (Universal Health Coverage [UHC], Human Development Index [HDI], Gender Inequality Index [GII], national budgets, and disease burden), institutional rankings (Quacquarelli Symonds [QS], Times Higher Education [THE], and Academic Ranking of World Universities [ARWU]), and individual attributes (gender and academic age). Outcomes were EDS counts by country/institution and scholar-level bibliometrics (citations excluding self-citations, modified H-index, and composite score).
Results: EDS were overwhelmingly based in high-income countries (97.9% career-long; 94.5% single-year) with the EURO region contributing ~48% of EDS and exhibiting highest densities (0.585 and 0.482 per 100,000), while low-income settings had ~0.002. The top 20 institutions hosted ~21% of all EDS. Women comprised 22.9% (career-long)…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.